Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serum Institute of India Pvt. Ltd.

http://www.seruminstitute.com/

Latest From Serum Institute of India Pvt. Ltd.

India’s COVID-19 Nightmare And How Pharma Is Holding Up

A COVID-19 second wave is wreaking havoc in India but pharma appears to be holding things together for now, stretching resources amid a dip in personnel attendance and supply chain strains. Limited vaccine supplies, a spurt in API prices and an inevitable third wave could mean further turbulence ahead.

India Commercial

UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit

After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?

Commercial Coronavirus COVID-19

Coronavirus Notebook: 1.2bn Vaccines Produced Worldwide, ROVI To Double Moderna Capacity, Valneva starts UK Phase II/III trial

The World Health Organization has updated progress with evaluations of two Chinese vaccines and Russia's Sputnik V, the UK has ordered 60 million more Pfizer/BioNTech doses, and the European Medicines Agency is looking at the use of baricitinib in COVID-19 patients requiring oxygen.

Europe United Kingdom

WHO Chief Scientist Warns Of 'Pandemic Within A Pandemic', Calls For New R&D Models

A high profile panel including the WHO's chief scientist and ministers of Norway and South Africa discussed critical dimensions pertaining to coronavirus vaccines and risks of a “pandemic within a pandemic” with the emergence of  SARS-CoV-2 variants. Funding gaps at the ACT Accelerator and extending the shelf life of vaccines were also deliberated.

Research & Development Coronavirus COVID-19
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Bilthoven Biologicals
UsernamePublicRestriction

Register